Mr Wang Zhiwei (front row, right), Vice-President of Guizhou Yibai, and Professor Rick Wong (front row, left), Vice-President (Research and Development) of HKBU, sign the cooperation agreement on behalf of the two parties to establish the “Hong Kong Baptist University ─ Guizhou Yibai Joint Research Platform for Translational Medicine and Drug Discovery”


貴州益伯副總裁汪志偉先生(前排右)與浸大副校長(研究及拓展)黃偉國教授(前排左)代表雙方簽署協議書,共同建立「香港浸會大學─貴州益佰轉化醫學與創新藥物聯合研究平台」

Date: 11 Dec 2014 (Thursday)

Archive

HKBU collaborates with a pharmaceutical company in Mainland China to establish joint research platform for translational medicine and drug discovery

浸大與內地製藥公司共建轉化醫學與創新藥物研究平台

HKBU and Guizhou Yibai Pharmaceutical Co Ltd (Guizhou Yibai) signed a cooperation agreement recently to establish the “Hong Kong Baptist University – Guizhou Yibai Joint Research Platform for Translational Medicine and Drug Discovery” with the aim of developing new combinational target-specific drugs.

The agreement signing ceremony was attended by representatives of the People’s Government of Guizhou Province, Guiyang Municipal Government, Guizhou Yibai and HKBU. Representatives from the People’s Government of Guizhou Province included Mr Wang Jiangping, Vice Governor; Mr Feng Shiwen, Deputy Secretary-General of Guizhou Provincial People’s Government; Mr Chen Jian, Director of Science and Technology Department; Mr Ma Ningyu, Deputy Director of the Commission of Industry and Information Technology; Mr Luo Xiangbin, Deputy Director of Food and Drug Administration; Ms Mao Youbi, Vice Mayor of the Guiyang Municipal Government; Ms Yang Ji, Head of the Yunyan District. Guizhou Yibai was represented by Ms Dou Qiling, President; Mr Lang Hongping, Mr Wang Zhiwei and Mr Zhang Shenggui, Vice-Presidents; Mr Zhang Linsheng, Assistant to President; Mr Li Gang, Director of Strategic Planning and Brand Promotion Departments; Professor He Fengci, Director of Technology; and Mr Yang Qingbo, Director of Technology Division. The HKBU delegation led by Professor Albert Chan, President and Vice-Chancellor, comprised of Professor Rick Wong, Vice-President (Research and Development); Professor Lu Aiping, Dean of the School of Chinese Medicine (SCM); and Dr Zhang Ge, Director of Technology Development Division.

In his speech, Professor Albert Chan said that Guizhou province, with its abundant Chinese herbal resources, has a distinct advantage in the production of Chinese medicines and the research and development of new drugs in Chinese medicine. Guizhou Yibai, a high-tech enterprise devoted to the research, development, production and sale of new drugs, shares the common goals of promoting Chinese medicine and contributing to good health and well-being with HKBU. He looked forward to the discovery of innovative drugs in the near future through joint research on translational medicine and drug discovery.

Addressing the audience, Mr Wong Jiangping, Vice Governor of Guizhou province, said that new drug development and the health industry in Guizhou enjoy the advantages of rich herbal resources, robust ethnic medicines industry as well as favourable policies of Guizhou province that support biomedical drug research. With the research platform established in Hong Kong and the production base in Guizhou, the collaboration would benefit from the strengths of the two parties and produce fruitful results.

Located in SCM’s new research base in the Hong Kong Science and Technology Park, the research platform managed by SCM is a channel for drug data mining and bioinformatics analysis which provides technical support for biomedical drug research. It is the objective of the two parties to gain national and regional research grants as well as register new drugs.

浸大與貴州益佰製藥股份有限公司早前簽署協議書,共同建立「香港浸會大學─貴州益佰轉化醫學與創新藥物聯合研究平台」,開發具有組合與靶向特徵的新藥。

出席簽署儀式的人士包括貴州省人民政府代表王江平副省長、副秘書長馮仕文先生、科技廳廳長陳堅先生、工信委常務副主任馬寧宇先生、食品藥品監督管理局副局長羅祥斌先生、貴陽市人民政府副市長毛有碧女士、貴陽市雲岩區人民政府區長楊繼女士、貴州益伯總裁竇啟玲女士、副總裁郎洪平先生、副總裁汪志偉先生、副總裁張聖貴先生、總裁助理張林生先生、品牌推廣部及戰略部總監李剛先生、科技總監何鳳慈教授和技術部部長楊青波先生。浸大則由校長陳新滋教授率領代表團出席,成員包括副校長(研究及拓展)黃偉國教授、中醫藥學院院長呂愛平教授、研究開發部主任張戈博士等。

陳新滋教授在致辭時表示,貴州的中草藥資源豐富,為當地的中藥材生產、中藥新產品開發提供了優越的條件,而貴州益佰是一家集新型藥品研究、開發、生產和銷售為一體的高新技術企業,其宗旨與浸大弘揚中醫藥、保障人類健康的目標不謀而合。他認為浸大中醫藥學院與貴州益佰合作是強強聯手,希望雙方共同開展的轉化醫學和創新藥物研究工作可以早日結出成功的果實。

王江平副省長在致辭時表示,在貴州發展新醫藥健康產業,能善用當地豐富的中草藥資源、發達的民族醫藥產業,以及政府支持生物醫藥科研的政策等優勢;這項與浸大携手建立的研究平台設在香港、生產基地則在貴州,相信必定能夠各自發揮所長,互補優勢。

該研究平台將設在中醫藥學院位於香港科學園的研究基地,由中醫藥學院負責日常管理,逐步建設和完善藥物數據挖掘和生物訊息分析平台,為創新生物醫藥的研發提供技術支援,朝著共同爭取國家及地區研究基金、聯合申報新藥註冊的目標邁進。